Last reviewed · How we verify
NCT03150238: POCD2017
Surgically Resected Crohn's Disease Patients: Prognostic Factors for Re-operation and New Score Building
trial testing observation of prognostic factors for relapse in Crohn Disease in 220 participants. Status unknown.
31 January 2019
Quick facts
| Lead sponsor | Istituto Clinico Humanitas |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 220 |
| Start date | 13 April 2017 |
| Primary completion | 31 January 2019 |
| Estimated completion | 31 May 2019 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- observation of prognostic factors for relapse
Conditions studied
- Crohn Disease — all drugs for Crohn Disease →
Sponsor
Istituto Clinico Humanitas
Who can join
Adults 18 to 65, any sex, with Crohn Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The project will consist of a multicentre, prospective, observational study with a total duration of 24 months. Clinical, endoscopic and ultrasound data will be collected in a dedicated database (on IG-IBD Register), which will be used to identify potential clinical, endoscopic and ultrasound risk factors of re-operation. These data could be merged into a shared score, to stratify patients according to the risk of post-surgical re- operation and to define an optimal therapeutic management in the post- operative period. Approximately 220 adult patients, with a defined diagnosis of CD, who underwent a surgery for CD in the previous 6 months will be enrolled.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03150238
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Crohn Disease
Currently open trials in the same condition.
- NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
- NCT07310095 — A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) · Phase 4 · recruiting
- NCT07364734 — Epidemiological Characteristics and Efficacy Evaluation of Difficult-To-Treat Crohn's Disease · recruiting
- NCT07170462 — Cranberry and Gut Health in Crohn's Disease · EARLY_PHASE1 · recruiting
- NCT07196722 — A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease · Phase 2, PHASE3 · recruiting
Other Istituto Clinico Humanitas trials
Trials by the same sponsor.
- NCT06944288 — Microbiota as Early Diagnostic and predictivE Factor for Osteoarthritic Degeneration and Microbial Contamination · NA · not yet recruiting
- NCT07358247 — Postoperative Outcomes of Single-stapled Anastomosis Combined With Transanal Natural Orifice Specimen Extraction · not yet recruiting
- NCT07362342 — RIght VEntricle Response to Major Lung Resection in VATS and Robotic Surgery · not yet recruiting
- NCT07346274 — Intra-operative Hypotension and Post-operative Lactate Level After Pancreatic-duodenectomy. · enrolling by invitation
- NCT07491419 — The Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome (ACT-FAST) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03150238 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istituto Clinico Humanitas
- Last refreshed: 12 May 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03150238.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing